EU approves Revolution Medicines’ Rasonque for metastatic pancreatic cancer
RVMD•The European Commission approved Revolution Medicines’ Rasonque (daraxonrasib) as a once-daily oral monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, regardless of RAS mutation status.
1. EU approval
The European Commission approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, regardless of RAS mutation status. The once-daily oral treatment is a monotherapy; patient access depends on country-specific pricing and reimbursement processes.




